|
Name |
Ophiobolin I
|
Molecular Formula | C25H36O3 | |
IUPAC Name* |
(1'R,2S,3S,3'S,5R,7'R,8'E,11'R)-8'-(hydroxymethyl)-1',3,4'-trimethyl-5-(2-methylprop-1-enyl)spiro[oxolane-2,12'-tricyclo[9.3.0.03,7]tetradeca-4,8-diene]-6'-one
|
|
SMILES |
C[C@H]1C[C@@H](O[C@@]12CC[C@]3([C@H]2C/C=C(\[C@H]4[C@H](C3)C(=CC4=O)C)/CO)C)C=C(C)C
|
|
InChI |
InChI=1S/C25H36O3/c1-15(2)10-19-12-17(4)25(28-19)9-8-24(5)13-20-16(3)11-21(27)23(20)18(14-26)6-7-22(24)25/h6,10-11,17,19-20,22-23,26H,7-9,12-14H2,1-5H3/b18-6-/t17-,19-,20+,22+,23-,24+,25-/m0/s1
|
|
InChIKey |
PWHAYWTWJLFKJT-MUKMEUIDSA-N
|
|
Synonyms |
Ophiobolin I; 110013-85-9; CHEMBL469706
|
|
CAS | NA | |
PubChem CID | 14035917 | |
ChEMBL ID | CHEMBL469706 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 384.6 | ALogp: | 3.9 |
HBD: | 1 | HBA: | 3 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 46.5 | Aromatic Rings: | 4 |
Heavy Atoms: | 28 | QED Weighted: | 0.653 |
Caco-2 Permeability: | -4.75 | MDCK Permeability: | 0.00001920 |
Pgp-inhibitor: | 0.973 | Pgp-substrate: | 0.011 |
Human Intestinal Absorption (HIA): | 0.034 | 20% Bioavailability (F20%): | 0.787 |
30% Bioavailability (F30%): | 0.874 |
Blood-Brain-Barrier Penetration (BBB): | 0.979 | Plasma Protein Binding (PPB): | 79.51% |
Volume Distribution (VD): | 2.169 | Fu: | 6.64% |
CYP1A2-inhibitor: | 0.024 | CYP1A2-substrate: | 0.572 |
CYP2C19-inhibitor: | 0.073 | CYP2C19-substrate: | 0.807 |
CYP2C9-inhibitor: | 0.064 | CYP2C9-substrate: | 0.054 |
CYP2D6-inhibitor: | 0.02 | CYP2D6-substrate: | 0.143 |
CYP3A4-inhibitor: | 0.927 | CYP3A4-substrate: | 0.535 |
Clearance (CL): | 14.925 | Half-life (T1/2): | 0.082 |
hERG Blockers: | 0.021 | Human Hepatotoxicity (H-HT): | 0.927 |
Drug-inuced Liver Injury (DILI): | 0.276 | AMES Toxicity: | 0.029 |
Rat Oral Acute Toxicity: | 0.367 | Maximum Recommended Daily Dose: | 0.827 |
Skin Sensitization: | 0.821 | Carcinogencity: | 0.122 |
Eye Corrosion: | 0.101 | Eye Irritation: | 0.112 |
Respiratory Toxicity: | 0.967 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004222 | 0.847 | D0E9KA | 0.282 | ||||
ENC001559 | 0.576 | D06AEO | 0.276 | ||||
ENC003209 | 0.554 | D04SFH | 0.261 | ||||
ENC005803 | 0.525 | D0D2TN | 0.261 | ||||
ENC005044 | 0.457 | D0V2JK | 0.258 | ||||
ENC005045 | 0.444 | D08PIQ | 0.250 | ||||
ENC005046 | 0.417 | D0I2SD | 0.250 | ||||
ENC003251 | 0.398 | D04GJN | 0.250 | ||||
ENC002982 | 0.387 | D0W2EK | 0.248 | ||||
ENC002981 | 0.348 | D0Y2YP | 0.248 |